Efficacy of turmeric in the treatment of digestive disorders: A systematic review and meta-analysis protocol

Systematic Reviews

Volumn 3, Issue 1, 2014, Pages

  Thavorn, Kednapa ^a   Mamdani, Muhammad M ^a,b,c,d   Straus, Sharon E ^a,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TURMERIC;

ARTICLE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CURCUMA LONGA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HOSPITALIZATION; HUMAN; IRRITABLE COLON; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SYSTEMATIC REVIEW (TOPIC); ULCERATIVE COLITIS; CURCUMA; GASTROINTESTINAL DISEASE; META ANALYSIS; METHODOLOGY; PHYTOTHERAPY; REVIEW; TREATMENT OUTCOME;

CURCUMA; GASTROINTESTINAL DISEASES; HUMANS; PHYTOTHERAPY; TREATMENT OUTCOME;

EID: 84907266350     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-3-71     Document Type: Article

References (41)

1. Digestive Diseases Statistics for the United States. [http://digestive.niddk.nih.gov/statistics/statistics.aspx].
2. National Digestive Disorders Prevalence & Impact Study Report, Establishing Digestive Health as a National Priority. [http://www.cdhf.ca/bank/document_en/25establishing-digestive-health-as-a-priority-for-canadians.pdf].
3. Ruhl C, Sayer B, Byrd-Holt D, Brown D. The burden of digestive diseases in the United States. Costs of Digestive Diseases 2009, Bethesda: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Everhart JE.
4. Lewison G. Gastroenterology in the UK: the Burden of Disease 1997, London: The Wellcome Trust.
5. Tillisch K. Complementary and alternative medicine for functional gastrointestinal disorders. Gut 2006, 55:593-596. 10.1136/gut.2005.078089, 1856117, 16609129.
6. Devesa Jorda F, Pellicer Bataller J, Ferrando Ginestar J, Borghol Hariri A, Bustamante Balen M, Ortuno Cortes J, Ferrando Marrades I, Llobera Bertran C, Sala Lajo A, Minana Morell M, Nolasco Bonmatí A, Fresquet Febrer JL. Consumption of medicinal herbs in patients attending a gastroenterology outpatient clinic. Gastroenterol Hepatol 2004, 27:244-249. 10.1016/S0210-5705(03)70453-1, 15056410.
7. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991, 57:1-7. 10.1055/s-2006-960004, 2062949.
8. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009, 14:141-153.
9. Sharma OP. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976, 25:1811-1812. 10.1016/0006-2952(76)90421-4, 942483.
10. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem 1999, 47:4297-4300. 10.1021/jf990308d, 10552805.
11. Shah BH, Nawaz Z, Pertani SA, Roomi A, Mahmood H, Saeed SA, Gilani AH. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem Pharmacol 1999, 58:1167-1172. 10.1016/S0006-2952(99)00206-3, 10484074.
12. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008, 267:133-164. 10.1016/j.canlet.2008.03.025, 18462866.
13. Mills S, Bone K. Principles and Practice of Phytotherapy 2000, London: Churchill Livingstone.
14. Rafatullah S, Tariq M, Al-Yahya MA, Mossa JS, Ageel AM. Evaluation of turmeric (Curcuma longa) for gastric and duodenal antiulcer activity in rats. J Ethnopharmacol 1990, 29:25-34. 10.1016/0378-8741(90)90094-A, 2345457.
15. Thamlikitkul V, Bunyapraphatsara N, Dechatiwongse T, Theerapong S, Chantrakul C, Thanaveerasuwan T, Nimitnon S, Boonroj P, Punkrut W, Gingsungneon V, Wongkonkatape S, Ekpalakorn W, Boontaeng N, Jesadaporn U, Taechaiya S, Petcharoen S, Riewpaiboon A, Adthasit R, Timsard S, Tenambergen ED. Randomized double blind study of Curcuma domestica Val. for dyspepsia. J Med Assoc Thai 1989, 72:613-620.
16. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006, 4:1502-1506. 10.1016/j.cgh.2006.08.008, 17101300.
17. Brinkhaus B, Hentschel C, Von Keudell C, Schindler G, Lindner M, Stutzer H, Kohnen R, Willich SN, Lehmacher W, Hahn EG. Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial. Scand J Gastroenterol 2005, 40:936-943. 10.1080/00365520510023134, 16173134.
18. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, Boers M. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009, 62:1013-1020. 10.1016/j.jclinepi.2008.10.009, 19230606.
19. Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012, 10:Cd008424. 4001731, 23076948.
20. Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols (PRISMA-P). [http://2013.colloquium.cochrane.org/abstracts/preferred-reporting-items-systematic-reviews-and-meta-analyses-protocols-prisma-p-2013].
21. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004, 127:1239-1255. 10.1053/j.gastro.2004.05.030, 15481001.
22. American International Health Alliance Protocol for diagnosis and treatment of peptic ulcer in adults 2002, Washington: American International Health Alliance, American International Health Alliance.
23. Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders. [http://www.romecriteria.org/assets/pdf/19_RomeIII_apA_885-898.pdf].
24. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005, 100:190-200. 10.1111/j.1572-0241.2005.41217.x, 15654800.
25. Gwee KA, Teng L, Wong RK, Ho KY, Sutedja DS, Yeoh KG. The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2009, 21:417-424. 10.1097/MEG.0b013e328317b89e, 19369829.
26. Veldhuyzen van Zanten SJ. The role of Helicobacter pylori infection in non-ulcer dyspepsia. Aliment Pharmacol Ther 1997, 11(Suppl 1):63-69.
27. Revicki DA, Rentz AM, Tack J, Stanghellini V, Talley NJ, Kahrilas P, De La Loge C, Trudeau E, Dubois D. Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol 2004, 2:769-777. 10.1016/S1542-3565(04)00348-9, 15354277.
28. Bamberg P, Caswell CM, Frame MH, Lam SK, Wong EC. A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients. J Gastroenterol Hepatol 1992, 7:577-585. 10.1111/j.1440-1746.1992.tb01489.x, 1362499.
29. Romano M, Cuomo A. Eradication of Helicobacter pylori: a clinical update. Med Gen Med 2004, 6:19.
30. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001, 48:272-282. 10.1136/gut.48.2.272, 1728206, 11156653.
31. Drossman DA, Li Z, Toner BB, Diamant NE, Creed FH, Thompson D, Read NW, Babbs C, Barreiro M, Bank L, Whitehead WE, Schuster MM, Guthrie EA. Functional bowel disorders: a multicenter comparison of health status and development of illness severity index. Dig Dis Sci 1995, 40:986-995. 10.1007/BF02064187, 7729289.
32. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997, 11:395-402. 10.1046/j.1365-2036.1997.142318000.x, 9146781.
33. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003, 17(Suppl 2):11-17.
34. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476. 10.1056/NEJMoa050516, 16339095.
35. Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, Mareya S, Forbes WP. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2009, 104:1452-1459. 10.1038/ajg.2009.83, 19491859.
36. Allen CJ, Parameswaran K, Belda J, Anvari M. Reproducibility, validity, and responsiveness of a disease-specific symptom questionnaire for gastroesophageal reflux disease. Dis Esophagus 2000, 13:265-270. 10.1046/j.1442-2050.2000.00129.x, 11284971.
37. Williford WO, Krol WF, Spechler SJ. Development for and results of the use of a gastroesophageal reflux disease activity index as an outcome variable in a clinical trial: VA Cooperative Study Group on Gastroesophageal Reflux Disease (GERD). Control Clin Trials 1994, 15:335-348. 10.1016/0197-2456(94)90031-0, 8001355.
38. Suggested risk of bias criteria for EPOC reviews. [http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/14%20Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews%202013%2008%2012.pdf].
39. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp].
40. Sterne J, Egger M, Moher D. Addressing reporting biases. Cochrane Handbook for Systematic Reviews of Interventions 2008, 317. England: John Wiley & Sons Ltd, Higgins J, Green S.
41. Chemoprevention Branch and Agent Development Committee Clinical development plan: Curcumin. J Cell Biochem 1996, 63:72-85. Chemoprevention Branch and Agent Development Committee.